Published in Curr Pharm Des on January 01, 2002
Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford) (2013) 0.98
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care (2010) 1.66
Hypereosinophilic syndrome: an update. Am J Hematol (2005) 1.27
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol (2006) 1.23
Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel (2010) 1.21
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol (2014) 1.11
Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects. DNA Cell Biol (2005) 1.11
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res (2011) 1.11
Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood (2003) 1.09
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol (2011) 1.07
Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem (2008) 1.07
Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem (2011) 1.07
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem (2010) 1.05
Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors. Antimicrob Agents Chemother (2011) 1.03
Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer (2007) 1.02
Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses (2003) 1.01
HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection. J Immunol (2008) 0.99
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol (2011) 0.97
Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res (2005) 0.96
Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol (2002) 0.96
Identification of an invasion regulatory domain within the core protein of syndecan-1. J Biol Chem (2004) 0.94
Rapid progression to simian AIDS can be accompanied by selection of CD4-independent gp120 variants with impaired ability to bind CD4. J Virol (2002) 0.93
Defining carbohydrate antigens as HIV vaccine candidates. Curr Pharm Des (2007) 0.91
Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine (2007) 0.91
A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response. Cancer Res (2004) 0.91
Fructose as a carbon source induces an aggressive phenotype in MDA-MB-468 breast tumor cells. Int J Oncol (2010) 0.89
Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol (2005) 0.89
Down modulation of human TLR3 function by a monoclonal antibody. Cell Immunol (2007) 0.88
Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in an ovariectomized Zucker rat model. Int J Oncol (2007) 0.88
A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins (2007) 0.87
Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother (2008) 0.87
Antigen binding of human IgG Fabs mediate ERK-associated proliferation of human breast cancer cells. DNA Cell Biol (2005) 0.86
Role of SA-Le(a) and E-selectin in metastasis assessed with peptide antagonist. Peptides (2002) 0.86
Deficiency in surface expression of E-selectin ligand promotes lung colonization in a mouse model of breast cancer. Int J Cancer (2005) 0.86
Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation. Biochemistry (2006) 0.86
HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins (2012) 0.85
Solid-state nanopore detection of protein complexes: applications in healthcare and protein kinetics. Small (2012) 0.84
Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology (2003) 0.84
Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. J Biol Chem (2003) 0.84
Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif (2005) 0.84
Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol (2010) 0.84
SA-Lea and tumor metastasis: the old prediction and recent findings. Hybrid Hybridomics (2002) 0.83
Click chemistry in peptide-based drug design. Molecules (2013) 0.82
Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly. Cytokine (2008) 0.82
Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes. Vaccine (2009) 0.82
Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry. BMC Cancer (2008) 0.82
Multiple antigenic mimotopes of HIV carbohydrate antigens: relating structure and antigenicity. J Biol Chem (2006) 0.81
Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant. Int J Oncol (2006) 0.81
Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine (2003) 0.81
A community-based approach to translational research addressing breast cancer disparities. Transl Behav Med (2011) 0.81
Cytokine recognition by human interleukin 5 receptor. Vitam Horm (2005) 0.81
Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1. Antimicrob Agents Chemother (2013) 0.80
Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int J Mol Med (2006) 0.80
Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens. J Biol Chem (2005) 0.80
Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology (2005) 0.80
Immunomodulatory effects of radiofrequency ablation in a breast cancer model. Immunol Invest (2010) 0.79
Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol (2013) 0.79
Carbohydrate targets in HIV vaccine research: lessons from failures. Immunotherapy (2009) 0.79
Receptor epitope usage by an interleukin-5 mimetic peptide. J Biol Chem (2005) 0.79
Targeting carbohydrate antigens in HIV vaccine development. Vaccine (2005) 0.79
Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86. J Immunol (2003) 0.79
Carbohydrate mimetic peptides augment carbohydrate-reactive immune responses in the absence of immune pathology. Cancers (Basel) (2011) 0.79
Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha. Biopolymers (2004) 0.78
Glycan mediated immune responses to tumor cells. Hum Vaccin (2011) 0.78
Multivalent and flexible PEG-nitrilotriacetic acid derivatives for non-covalent protein pegylation. Pharm Res (2011) 0.78
Immune surveillance as a rationale for immunotherapy? Hum Vaccin (2007) 0.78
(1)H nuclear magnetic resonance metabolomic analysis of mammary tumors from lean and obese Zucker rats exposed to 7,12-dimethylbenz[a]anthracene. Int J Mol Med (2007) 0.78
Recruitment pharmacophore for interleukin 5 receptor alpha antagonism. Biopolymers (2007) 0.78
Carbohydrate mimotopes in the rational design of cancer vaccines. Curr Top Med Chem (2005) 0.78
Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics. J Chem Inf Model (2016) 0.77
Use of surrogate antigens as vaccines against cancer. Hybrid Hybridomics (2002) 0.77
Moving a Carbohydrate Mimetic Peptide into the clinic. Hum Vaccin Immunother (2014) 0.77
His-tag binding by antibody C706 mimics β-amyloid recognition. J Mol Recognit (2010) 0.77
Gender and location of CRC in IBD: implications for surveillance protocols. Inflamm Bowel Dis (2013) 0.77
Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens for cancer vaccination. Crit Rev Immunol (2007) 0.77
Structure-based rationale for interleukin 5 receptor antagonism. Curr Pharm Des (2008) 0.76
Proteins, recognition networks and developing interfaces for macromolecular biosensing. J Mol Recognit (2004) 0.76
Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother Biol Response Modif (2005) 0.76
Modular, self-assembling peptide linkers for stable and regenerable carbon nanotube biosensor interfaces. J Mol Recognit (2006) 0.76
Strategies in cancer vaccines development. Int J Parasitol (2003) 0.76
Biosensor analysis of receptor-ligand interactions. Methods Mol Biol (2004) 0.75
A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α. Biochemistry (2011) 0.75
Hilary Koprowski, MD December 5, 1916-April 11, 2013. Monoclon Antib Immunodiagn Immunother (2014) 0.75
Application of transcriptome analysis to clinical pharmacology studies. Curr Mol Med (2005) 0.75
Hilary Koprowski, MD: A lifetime of work. Monoclon Antib Immunodiagn Immunother (2014) 0.75
Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring. Org Biomol Chem (2017) 0.75
Structure-based peptide mimicry of tumor-associated antigens. Monoclon Antib Immunodiagn Immunother (2013) 0.75
Biologics and molecular recognition: Mike Brigham-Burke memorial issue. J Mol Recognit (2012) 0.75
1H-NMR metabolic markers of malignancy correlate with spontaneous metastases in a murine mammary tumor model. Int J Oncol (2005) 0.75
The Future of . Monoclon Antib Immunodiagn Immunother (2020) 0.75
Cancer immunotherapeutics: evolution of monoclonal antibodies to peptide immunogens. Monoclon Antib Immunodiagn Immunother (2014) 0.75
Special issue on Catholic social teaching and healthcare reform. Linacre Q (2016) 0.75
Psoriatic arthritis. Postgrad Med (1995) 0.75
Laboratory tests for rheumatic diseases. Postgrad Med (1995) 0.75
Coiled coil miniprotein randomization on phage leads to charge pattern mimicry of the receptor recognition determinant of interleukin 5. J Mol Recognit (2002) 0.75